acute-gvhd

Documents about acute-gvhd

• T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)#979955ClinicalTrials.gov
• Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)#1085534ClinicalTrials.gov
• Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)#1172228ClinicalTrials.gov
• Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)#1260630ClinicalTrials.gov
• Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment#1350247ClinicalTrials.gov
• Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)#1377849ClinicalTrials.gov
• Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)#1293269ClinicalTrials.gov
• Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)#874302ClinicalTrials.gov
• Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )#1339746ClinicalTrials.gov
• Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease#1044563ClinicalTrials.gov
• Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation#903455ClinicalTrials.gov
• Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD#1295769ClinicalTrials.gov
• Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)#1086656ClinicalTrials.gov
• PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant#851058ClinicalTrials.gov
• Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)#1047956ClinicalTrials.gov
• Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)#829488ClinicalTrials.gov
• A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD#899736ClinicalTrials.gov
• Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation#1381875ClinicalTrials.gov
• Itacitinib for Low Risk GVHD#1010232ClinicalTrials.gov
• Ectoin Dermatitis Cream 7% as First-line Therapy of Acute Skin Graft Versus Host Disease#1030676ClinicalTrials.gov
• Haplo Peripheral Blood Sct In GVHD Prevention#1282314ClinicalTrials.gov
• Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD#834776ClinicalTrials.gov
• Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)#1030343ClinicalTrials.gov
• Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants#1419959ClinicalTrials.gov
• Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant#831445ClinicalTrials.gov
• Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients#873493ClinicalTrials.gov
• Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease#1138725ClinicalTrials.gov
• MTX and Steroid for III-IV aGVHD Treatment#1140397ClinicalTrials.gov
• A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)#1030334ClinicalTrials.gov
• MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib#854249ClinicalTrials.gov
• Ruxolitinib for Steroid-refractory GVHD#1230069ClinicalTrials.gov
• Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD#1046926ClinicalTrials.gov
• Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD#906086ClinicalTrials.gov
• Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation#1337227ClinicalTrials.gov
• Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease#1075642ClinicalTrials.gov
• Pediatric GVHD Low Risk Steroid Taper Trial#481651ClinicalTrials.gov
• Safety and Efficacy Study of hAESCs Therapy for aGVHD#1337023ClinicalTrials.gov
• Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD#1184946ClinicalTrials.gov
• Electronic Database for the Follow up of the ATG_FamilyStudy#1363326ClinicalTrials.gov
• Intestinal Microbiome-based Research for the Prevention of Acute GVHD#1372063ClinicalTrials.gov
• A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease#1365712ClinicalTrials.gov
• The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease#810426ClinicalTrials.gov
• Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD#811515ClinicalTrials.gov
• FMT for Steroid Resistant Gut Acute GVHD#1060716ClinicalTrials.gov
• Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant#1100876ClinicalTrials.gov
• MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients#245547ClinicalTrials.gov
• Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT#866851ClinicalTrials.gov
• Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer#1089150ClinicalTrials.gov
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)#1127309ClinicalTrials.gov
• Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation#1353025ClinicalTrials.gov